Going stromal with docetaxel

Abraxane nab-paclitaxel is the model example of how an old microtubule-stabilizing chemotherapy can be revitalized through a new nanoparticle formulation. Now, Ontario Institute for Cancer Research scientists have developed glycopolymer-conjugated docetaxel nanoparticles that outperform Abraxane in mouse models of breast cancer.¹

The Ontario Institute for Cancer Research (OICR) is backing the program with $1.5 million to take it to the clinic. The expectation is that the product's ability to target the tumor stroma rather than the tumor itself will differentiate it from Abraxane and other chemotherapeutic formulations...